Jalon Therapeutics' goal is to create novel therapies that inhibit vital tumour signalling pathways that are currently untargeted.
Jalon Therapeutics has raised $465K in total funding. The most recent round was Debt Financing. The last funding was announced in November 2022.
Jalon Therapeutics's investors include Bpifrance.
Jalon Therapeutics is headquartered in Paris, France.
Jalon Therapeutics' goal is to create novel therapies that inhibit vital tumour signalling pathways that are currently untargeted.
Jalon Therapeutics is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Jalon Therapeutics — Funding & Investors." VCBacked, November 29, 2022, https://www.vcbacked.co/company/jalon-therapeutics. Accessed November 13, 2026.
VCBacked. (2022). Jalon Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/jalon-therapeutics
{{cite web |title=Jalon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/jalon-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Jalon Therapeutics? Request a listing update